Quantcast

Latest Protease Stories

2008-10-28 09:00:19

SOUTH SAN FRANCISCO, Calif., Oct. 28 /PRNewswire/ -- Catalyst Biosciences, Inc., a pioneer in the discovery and development of engineered proteases known as Alterase(TM) therapeutics, has appointed Todd Lorenz, M.D., as the company's Chief Medical Officer. Dr. Lorenz's career encompasses nearly 20 years of experience focused on the clinical development of novel medicines. "We are excited to welcome Dr. Lorenz to the Catalyst team," said Nassim Usman, Ph.D., Chief Executive Officer of...

aa185f81ff15bd120dd4241e5fcaddcc
2008-10-01 16:18:19

Researchers have speculated about the process, but never known until now After improving the sensitivity of nuclear magnetic resonance (NMR), researchers at the University of Missouri actually watched the HIV-1 protease mature from an inactive form into an active infection. This process has never been directly visualized before. The findings appear today in the journal Nature. "We actually saw the process occur," said Chun Tang, assistant professor of biochemistry in the MU School of Medicine...

2008-09-08 09:00:52

BRISBANE, Calif., Sept. 8 /PRNewswire-FirstCall/ -- InterMune, Inc. today announced that Steven B. Porter, M.D., Ph.D., Chief Medical Officer of InterMune, will present at the Robert W. Baird & Co. Small Cap Healthcare Conference in New York on September 10, 2008 at 10:30 a.m. EDT. To access a live audio webcast of the presentation, investors and other interested parties may log on to the investor relations page of InterMune's corporate website at http://www.intermune.com/. The...

2008-08-29 12:01:17

BRISBANE, Calif., Aug. 29 /PRNewswire-FirstCall/ -- InterMune, Inc. today announced that Daniel G. Welch, Chairman, CEO and President of InterMune, will present at the Thomas Weisel Partners Healthcare Conference in Boston on September 4, 2008 at 10:55 a.m. EDT. To access a live audio webcast of the presentation, investors and other interested parties may log on to the investor relations page of InterMune's corporate website at http://www.intermune.com/. The company recommends logging on...

2008-07-30 18:00:54

BRISBANE, Calif., July 30 /PRNewswire-FirstCall/ -- InterMune, Inc. today announced that Daniel G. Welch, Chairman, CEO and President of InterMune, will present at the BMO Capital Markets 2008 Focus on Healthcare Conference in New York on August 6, 2008 at 10:00 a.m. EDT. To access a live audio webcast of the presentation, investors and other interested parties may log on to the investor relations page of InterMune's corporate website at http://www.intermune.com/. The company recommends...

2007-06-07 15:00:41

Roche has recalled HIV drug Viracept in Europe and other world regions, excluding the US and Canada, over a potential contamination. As one of the older protease inhibitors, Viracept is prescribed to few patients and its recall will not significantly change current HIV market dynamics. However, it may cause Roche to lose the remaining patients as physicians are forced to switch to newer products. According to Roche, analysed batches of the recalled drug showed "chemical impurities"...

2005-10-31 13:47:03

DALLAS "“ Oct. 31, 2005 "“ A molecule consisting of two "cages" of metallic atoms bound to carbon has shown great promise in preliminary tests of becoming a new weapon in the anti-HIV arsenal, researchers at UT Southwestern Medical Center report. The molecule "“ called metallacarborane "“ and its variants appear to fight HIV protease, an enzyme critical in the virus' life cycle. Protease inhibitors are some of the key drugs used to fight HIV/AIDS, but they have side...

2005-10-24 21:04:23

Bethesda, MD "“ The leech has recently confirmed its biomedical interest for scientists by showing that it contains an extensive list of new potential molecules that may become useful tools in the treatment of cardiovascular diseases. The details of this research appear in the October issue of Molecular and Cellular Proteomics, an American Society for Biochemistry and Molecular Biology journal. Scientists have increasingly turned to blood-feeding invertebrates as a source for drugs and...

2005-09-17 10:13:04

Single protein triggers the glories of the season, researchers say HealthDay News -- Autumn's joyous pageant of red, yellow and gold relies on a single protein, new research reveals. The protein -- with the less-than-poetic name of FtsH6 -- degrades a second compound that spends most of the year holding tight to the green chlorophyll in leaves. As this compound (called LHCII) slips away, hidden pigments of red and yellow are revealed, explain researchers at Umea Plant Science Center in...

2005-08-01 18:34:46

HOUSTON, Aug. 1, 2005 "“ Researchers from Rice University's Center for Biological and Environmental Nanotechnology (CBEN) have developed a "smart" beacon hundreds of times smaller than a human cell that is programmed to light up only when activated by specific proteases. Altered expression of particular proteases is a common hallmark of cancer, atherosclerosis, and many other diseases. In the September issue of the journal Biochemical and Biophysical Research Communications, lead...


Word of the Day
barratry
  • The offense of persistently instigating lawsuits, typically groundless ones.
  • An unlawful breach of duty on the part of a ship's master or crew resulting in injury to the ship's owner.
  • Sale or purchase of positions in church or state.
This word ultimately comes from the Old French word 'barater,' to cheat.
Related